As U.S. tariffs loom, Canada should use AI to fight back
Our Chief Policy and Partnerships Officer, Richard Gold, argues that Canada has a unique opportunity to become a global leader in AI-assisted drug discovery by leveraging its strong scientific expertise and biomedical data infrastructure. To reduce reliance on the U.S., Canada must invest in large, open datasets, streamline regulations, and foster collaboration between government, academia, and […]
In Vivo features Conscience among leading nonprofits addressing biopharma market failures
In Search Of Rare Disease Treatments, Nonprofits Can Lead the Charge Read the full article in In Vivo »
Canada Can Confront US Tariffs by Liberating Innovators
Our Chief Policy and Partnerships Officer, Richard Gold, argues that if Trump goes ahead with his tariffs, Canada should use intellectual property as a weapon against the threat to national economic security – a bold step that would allow Canada to exploit its wealth of academic knowledge to produce lower-cost medicines and ramp up AI-assisted […]
Forbes features top-scoring CACHE 2 team and highlights importance of participation from the Global South
How Can AI Help Discover ‘New’ Drugs Against COVID-19 In Brazil? Read the full article in Forbes »
Chemical & Engineering News features Conscience and top CACHE 2 participants
Open-source competition finds potential coronavirus drugs Read the full article on Chemical & Engineering News »
KBIA news features CACHE 2 participant Dmitri Kireev and Conscience CEO Ryan Merkley
MU researcher’s AI model advances coronavirus drug development Read the full article on KBIA News »
The Logic features top-scoring CACHE 2 team and Conscience CEO Ryan Merkley
The global contest, run by Toronto’s Conscience, hunting for the best AI tools to find new medicines Read the full article on The Logic »
The Globe & Mail talks with Conscience CEO Ryan Merkley about AI and drug discovery
In the quest for new medicines, developers seek to make AI their divining rod Read the full article on the theglobeandmail.com
CMU-UBC Team Wins Challenge To Advance Parkinson’s Disease Research
From the Department of Chemistry Mellon College of Science Read the full article on cmu.edu/chemistry/news.
Open-source competition finds potential candidates for Parkinson’s disease drugs
Challenge identifies 7 small molecules for further study Read the full article on cen.acs.org.
Open science contest uses AI to ID possible hits for Parkinson’s, side-stepping ‘patent-driven approach’
While any discovery that could lead to new Parkinson’s treatments is “worthy of attention,” the findings must be tempered with “an understanding of the process that follows,” Conscience CEO Ryan Merkely said. Read the full article on www.fiercebiotech.com.
